VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Tolaney Discusses Pertuzumab in HER2+ Breast Cancer

Sara M. Tolaney, MD, MPH
Published: Thursday, Sep 07, 2017



Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

The APHINITY trial showed that adding pertuzumab to chemotherapy and trastuzumab (Herceptin) statistically improved disease-free survival, but the difference was small.

Tolaney says that the patients who benefit significantly from pertuzumab are those who have node-positive hormone receptor-negative disease.
 


Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

The APHINITY trial showed that adding pertuzumab to chemotherapy and trastuzumab (Herceptin) statistically improved disease-free survival, but the difference was small.

Tolaney says that the patients who benefit significantly from pertuzumab are those who have node-positive hormone receptor-negative disease.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x